Pragmatic randomised trials using routine electronic health records: putting them to the test
BMJPublished 7 February 2012Open access
Tjeerd van Staa, Ben Goldacre, Martin Gulliford, Jackie Cassell, Munir Pirmohamed, Adel Taweel
Citations173
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Using electronic health records to enter patients into randomised trials of treatments in real time could provide the answer to what to prescribe for a patient in general practice when the choice of treatments has a limited evidence base.
Abstract
What to prescribe for a patient in general practice when the choice of treatments has a limited evidence base? Tjeerd-Pieter van Staa and colleagues argue that using electronic health records to enter patients into randomised trials of treatments in real time could provide the answer
Keywords
MedicineHealth ProfessionsEconomics, Econometrics and Finance
The LancetExternal validity of randomised controlled trials: “To whom do the results of this trial apply?”
2,438 Citations2005Peter M. Rothwell
A review of the determinants of external validity in trial publications and systematic reviews is usually inadequate, a checklist for clinicians is presented, and recommendations for greater consideration of External validity in the design and reporting of RCTs are made.
Journal of Clinical EpidemiologyA pragmatic–explanatory continuum indicator summary (PRECIS): a tool to help trial designers
1,398 Citations2009Kevin E. Thorpe, Merrick Zwarenstein +9 more
A tool to assist trialists in making design decisions that are consistent with their trial's stated purpose is proposed, with 10 key domains and which identifies criteria to help researchers determine how pragmatic or explanatory their trial is.
Journal of Clinical EpidemiologyExplanatory and Pragmatic Attitudes in Therapeutical Trials
1,260 Citations2009Daniel Schwartz, J Lellouch
Most therapeutic trials are inadequately formulated from the earliest stages of their conception, and it often occurs that one type of approach is ethically less defensible than the other, or may even be ruled out altogether on ethical grounds.
BMJGood medical practice
765 Citations2011J Snape, Bruce M. Elliott
In geriatric and general medicine rectal examination is important other than for detecting rectal tumours or assessing the prostate, as has been emphasised in this paper.
BMJRethinking pragmatic randomised controlled trials: introducing the "cohort multiple randomised controlled trial" design
499 Citations2010Clare Relton, David Torgerson +2 more
Clare Relton and colleagues outline the new “cohort multiple randomised controlled trial” design, which could help address the problems associated with existing approaches in pragmatic trials.
Canadian Medical Association JournalA pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers
409 Citations2009Kevin E. Thorpe, Merrick Zwarenstein +9 more
A tool to assist trialists in making design decisions that are consistent with their trial's stated purpose is proposed, with 10 key domains and which identifies criteria to help researchers determine how pragmatic or explanatory their trial is.
Health Technology AssessmentFactors that limit the quality, number and progress of randomised controlled trials.
388 Citations1999Prescott, Counsell +8 more
Health Technology AssessmentThe role of expectancies in the placebo effect and their use in the delivery of health care: a systematic review.
360 Citations1999Rosemary Crow, Heather Gage +4 more
HTA reports may be freely reproduced for the purposes of private research and study and may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising.
Clinical MedicineBest research for best health: a new national health research strategy
270 Citations2006Timothy W. Evans
A new national health research strategy sets out the authors' goals for research and development over the next five years and demonstrates the Government's commitment to creating a vibrant research environment that contributes to the health and wealth of the nation.
Social Science & MedicineInformed consent for clinical trials: in search of the “best” method
136 Citations1998Sarah Edwards, Richard Lilford +2 more
There is some evidence to suggest that there is an optimal amount of information which enhances patient understanding and which might, in turn, reduce anxiety, although the studies were not altogether conclusive.
BMJTesting Treatments: Better Research for Better Healthcare
130 Citations2006Ike Iheanacho
This oxymoronic term refers to an acute awareness of and readiness to admit personal and profession-wide uncertainties about key healthcare questions and dilemmas and encapsulates an attitude seen in all the best doctors.
Europe PMC (PubMed Central)Testing Treatments: Better Research for Better Healthcare
130 Citations2006Imogen Evans, Hazel Thornton +2 more
Testing Treatments urges everyone to get involved in improving current research and future treatment, and outlines practical steps that patients and doctors can take together.
Journal of Medical EthicsWhy we should not seek individual informed consent for participation in health services research
95 Citations2002Jackie Cassell, Alys Young
Ethics committees now require that individuals give informed consent to much health services research, in the same way as for clinical research, which is misguided and alternative forms of community consent should be actively pursued.
The American Journal of BioethicsResearch Exceptionalism
70 Citations2010James Wilson, David Hunter
It is argued that the reasons typically offered to justify the present system of research regulation fail to show that research should be subject to more stringent regulation than other equally risky activities.
British Journal of Clinical PharmacologyAvailability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization
55 Citations2006Johan C. F. Van Luijn, Frank W.J. Gribnau +1 more
For most new medicines evidence-based assessment of the (added) therapeutic value is not really possible at the moment of market authorization.
The American Journal of BioethicsHuman Dignity and Transhumanism: Do Anthro-Technological Devices Have Moral Status?
51 Citations2010Fabrice Jotterand
Whether such a concept, as used in the Universal Declaration on Bioethics and Human Rights, is indeed a useful tool for bioethical debates is critically assessed and considered within the context of the development of emerging technologies, that is, with a particular focus on transhumanism.
BMJBritain's gift: a “Medline” of synthesised evidence
49 Citations2001Richard Smith, Iain Chalmers
The British government has the chance to match Medline by funding universal free access to what might be described as “a Medline of synthesised, reliable, and up to date evidence”, which could be even more useful to clinicians and patients and has the potential to change health care across the world.
BMJGiving medicine a fair trial
35 Citations2000Richard Ashcroft
The debate in research ethics should now focus on the usability of clinical trial evidence and the fairness of the design and timing of trials.
TrialsCluster randomised trial in the General Practice Research Database: 1. Electronic decision support to reduce antibiotic prescribing in primary care (eCRT study)
32 Citations2011Martin Gulliford, Tjeerd van Staa +9 more
A cluster randomised trial is implemented to test the effectiveness of an electronic record-based intervention at achieving a reduction in antibiotic prescribing at consultations for respiratory illness in patients aged 18 and 59 years old in intervention family practices as compared with controls.
PubMedEthical issues. How can we distinguish clinical research from innovative therapy?
22 Citations1994John D. Lantos
There are identifiable communities (ethnic groups) that are specifically effected by certain genetic diseases, as well as communities consisting of patients who have certain nongenetic diseases, which should be consulted and allowed to participate in the process of devising strategies to evaluate new therapies.